Genor Biopharma Holdings Limited (HK:6998)
:6998
Want to see HK:6998 full AI Analyst Report?
6998 Stock Chart & Stats
HK$3.06
HK$0.04(2.16%)
At close: 4:00 PM EST
HK$3.06
HK$0.04(2.16%)
Day’s Range― - ―
52-Week RangeHK$1.71 - HK$5.60
Previous CloseN/A
Volume193.50K
Average Volume (3M)909.38K
Market Cap
HK$3.53B
Enterprise ValueHK$1.34B
Total Cash (Recent Filing)HK$1.06B
Total Debt (Recent Filing)HK$1.49B
Price to Earnings (P/E)5.1
Beta0.45
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding2,011,213,700
10 Day Avg. Volume879,300
30 Day Avg. Volume909,383
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.17
Price to Sales (P/S)1.86
P/FCF Ratio11.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Material 2025 Profitability TurnaroundIn 2025 Genor delivered a step-change to sustained profitability with robust EBIT and net margins, indicating the business model can generate operating leverage. If management sustains revenue and gross margins, this improves capacity to fund R&D, commercial expansion and manufacturing at scale.
Quality Cash Generation In 2025Free cash flow nearly matching net income signals earnings quality and internal funding ability. Positive FCF provides durable flexibility to service debt, fund capex for large-scale manufacturing, and support commercial rollouts without reliance on external equity in the medium term.
Meaningful Equity Base And Moderate LeverageA sizeable equity base and moderate leverage afford financial flexibility for biologics manufacturing and development cycles. This capital structure supports strategic investments, potential CDMO growth and cushions macro shocks relative to peers with weaker equity buffers.
Bears Say
Historical Revenue And Earnings VolatilityThe company's history of zero revenue years and multi-year losses implies execution and commercialization risk. Such volatility weakens confidence that 2025 results are repeatable; customers, partners and payers may require sustained performance before long-term contracts or premium pricing follow.
Sharp Increase In DebtA rapid rise in debt raises refinancing and interest burden risk, potentially constraining R&D and manufacturing capex if cash generation weakens. Even with moderate D/E, the sudden shift in funding mix can stress liquidity under adverse cycles or slow revenue, affecting strategic optionality.
Prior Negative Cash Flow HistoryA multi-year history of negative operating cash flow indicates the firm has not yet proven stable cash generation across cycles. The 2025 swing may reflect base effects; without demonstrated multi-year FCF consistency, funding for long-term biologics programs remains less certain.
Genor Biopharma Holdings Limited News
6998 FAQ
What was Genor Biopharma Holdings Limited’s price range in the past 12 months?
Genor Biopharma Holdings Limited lowest stock price was HK$1.71 and its highest was HK$5.60 in the past 12 months.
What is Genor Biopharma Holdings Limited’s market cap?
Genor Biopharma Holdings Limited’s market cap is HK$3.53B.
When is Genor Biopharma Holdings Limited’s upcoming earnings report date?
Genor Biopharma Holdings Limited’s upcoming earnings report date is Sep 02, 2026 which is in 88 days.
How were Genor Biopharma Holdings Limited’s earnings last quarter?
Genor Biopharma Holdings Limited released its earnings results on Mar 27, 2026. The company reported HK$0.375 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.375.
Is Genor Biopharma Holdings Limited overvalued?
According to Wall Street analysts Genor Biopharma Holdings Limited’s price is currently Overvalued.
Does Genor Biopharma Holdings Limited pay dividends?
Genor Biopharma Holdings Limited does not currently pay dividends.
What is Genor Biopharma Holdings Limited’s EPS estimate?
Genor Biopharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genor Biopharma Holdings Limited have?
Genor Biopharma Holdings Limited has 2,011,213,700 shares outstanding.
What happened to Genor Biopharma Holdings Limited’s price movement after its last earnings report?
Genor Biopharma Holdings Limited reported an EPS of HK$0.375 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.857%.
Which hedge fund is a major shareholder of Genor Biopharma Holdings Limited?
Currently, no hedge funds are holding shares in HK:6998
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulising crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company's product candidates under clinical trials include GB262, GB264, GB265, and GB 266 for the treatment of cancer. Genor Biopharma Holdings Limited was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
JW (Cayman) Therapeutics Co. Ltd.
―
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
―
Zhaoke Ophthalmology Ltd.
―
Immunotech Biopharm Ltd
―